ARCHIVES

Vectibix Non-Inferior to Erbitux In Wild-Type Metastatic Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads

August 8, 1980

Funding Opportunities.

May 24, 2002

ASCO Briefing Highlights Seven Studies That Could Change Clinical Practice

May 29, 2009

New ACS Program Honors Mary Lasker

August 31, 1984

Detroit’s “Dr. Vee” Honored For 50 Years In Medicine.

November 9, 2001

Sen. Arlen Specter Remembered as Champion Of Federal Biomedical Resesarch Funding

October 19, 2012